Trial reportClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.
Trial report in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03782532 (A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Who cites it
7 citing papers in PubMed.
- Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry.Advances in therapy · 2026Observational
- MG-K10 in Moderate-to-Severe Asthma: Extending the Dosing Interval Without Compromising Efficacy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Review
- Triggering mechanisms of acute thunderstorm asthma: epithelial barrier disruption and immune dysregulation.Respiratory research · 2026Review
- Dupilumab Improves Lung Function and Reduces Severe Exacerbations in Patients from China with Type 2 Asthma: A Subgroup Analysis of a Phase 3 Randomized Trial.Journal of asthma and allergy · 2026Article
- Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma.Mediators of inflammation · 2025Review
- Phenotypes and endotypes of cough in asthma.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAsthma prevalence is increasing in the Asia-Pacific region. China and India account for > 35% of the world's population and are often underrepresented in clinical studies. This phase 3 study (NCT03782532) evaluated efficacy and safety of dupilumab, a monoclonal antibody blocking interleukin-4/13 signalling, in patients with persistent asthma from China and India.
methodsPatients (≥ 12 years) were randomised 1:1 to dupilumab 200 mg or matched placebo every 2 weeks for 24 weeks (primary analysis population: blood eosinophils ≥ 150 cells/μL or fractional exhaled nitric oxide ≥ 25 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 300 mg OCS). PRIMARY ENDPOINT: change from baseline to week 12 in forced expiratory volume in 1 s (FEV
resultsIn the primary analysis population (n = 414), change in FEV
conclusionDupilumab significantly improved lung function and asthma control, numerically reduced asthma exacerbations, and was well tolerated in patients from China and India with persistent asthma and evidence of either type 2 inflammation or OCS maintenance.
trial registrationClinicalTrials.gov identifier: NCT03782532.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.